|
||||||||||||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||
Overview
Irritable bowel syndrome (IBS) is a highly misunderstood functional bowel disorder that is underreported and underdiagnosed. Because IBS can be challenging to diagnose and manage, it is important that clinicians stay up-to-date on current developments of diagnostic and treatment options in IBS.
Objectives
Recognize the symptoms of IBS and employ ACG guidelines and Rome III criteria to make a symptom-based diagnosis of IBS
Implement a patient-centered and evidence-based approach to the treatment of IBS, taking patientsÕ treatment goals into consideration as well as the efficacy, safety, and mechanisms of action of available treatment options
Faculty
Louis Kuritzky, MD
Clinical Assistant Professor
Dept. of Community Health & Family Medicine
University of Florida
Gainesville, FL
David A. Peura, MD
Professor of Medicine
University of Virginia Health Sciences Center
Charlottesville, VA
Overview
More than 20 million people in the United States are affected by diabetes, with 1.5 million new cases appearing each year. Of this population, nearly 65% will die from heart disease or stroke, a rate that is 4-times higher than in the non-diabetic population. Individualized and early glycemic control is critical in the prevention and management of diabetes and in reducing cardiovascular risk. This activity will expose attendees to the relationship between insulin resistance, type 2 diabetes, and the resulting cardiovascular risk in an effort to uncover effective treatment strategies and patient-based therapeutic options.
Objectives
Utilize appropriate glucose-lowering agents to reduce A1C to * 7.0%
Minimize adverse events and cardiovascular risk associated with glycemic therapy by employing appropriate glucose, blood pressure, and serum cholesterol agents
Faculty
Silvio Inzucchi, MD
Professor of Medicine
Department of Internal Medicine
Yale University School of Medicine
New Haven, CT
Stan Schwartz, MD, FACE, FACP
University of Pennsylvania Medical Group
Hospital of the University of Pennsylvania
Philadelphia, PA
Overview
Bipolar disorder (BD) and major depressive disorder (MDD) are two of the most prevalent psychiatric disorders in adults. These conditions are associated with overlapping disorders of mood including anxiety and depression; differentiating the two disorders can be difficult and can lead to misdiagnosis and mismanagement. This activity will focus on practical approaches to the diagnosis and management of the Òdifficult-to-treatÓ patient presenting with depression associated with MDD and BD.
Objectives
Recognize overlapping symptomatology and comorbid psychiatric disorders that can complicate the differential diagnosis of depression
Design and implement practical strategies to diagnosis and manage the difficult-to-treat patient with depression associated with major depressive disorder and bipolar disorder
Faculty
J. Sloan Manning, MD
Adjunct Associate Professor
University of North Carolina - Chapel Hill
Co-Director, Mood Disorders Clinic
Moses Cone Family Practice Residency
Greensboro, NC
Linda Carpenter, MD
Associate Professor
Psychiatry and Human Behavior
Brown University Medical School
Butler Hospital
Providence, RI
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the benefits and limitations of current treatment options for herpes zoster and postherpetic neuralgia (PHN)
Evaluate clinical trial results of the herpes zoster vaccine and discuss current recommendations of the Advisory Committee on Immunization Practices for the prevention of herpes zoster
Faculty
M. Susan Burke, MD, FACP
Clinical Assistant Professor of Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania
Director, Internal Medicine Clinical Care Center
Lankenau Hospital
Wynnewood, PA
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Gregory L. Brotzman, MD
Professor of Family and Community Medicine
Medical College of Wisconsin
Milwaukee, WI
Martin C. Mahoney, MD, PhD
Director, Cancer Prevention & Detection Center
Roswell Park Cancer Institute
Associate Professor of Family Medicine
State University of New York at Buffalo
Buffalo, NY
Overview
This program will underscore the need for early, aggressive, combination BP treatment in order to reach JNC 7 goals, in light of the effect hypertension and diabetes has on the pathogenesis of hypertensive renal damage. It will explain the mechanisms of action of the various antihypertensive drug classes and how clinicians can use this understanding when selecting a drug regimen. Based on recent and ongoing trials, the safest and most efficacious drug combinations will be discussed.
Objectives
Develop appropriate combination therapy regimens individualized to each diabetic hypertensive patientÕs established risk and comorbid conditions
Demonstrate an understanding of the role of renin-aniotensin-aldosterone system blockers in the treatment of hypertension, the prevention of new onset diabetes, and the prevention of progression in diabetic nephropathy by selecting the most appropriate treatment regimen for diabetic hypertensive patients
Faculty
Philip Altus, MD, MACP
Professor of Medicine Emeritus
University of South Florida
Tampa, FL
Raymond R. Townsend, MD
Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Overview
Four million people in the United States suffer from neuropathic pain, a condition that is often difficult to diagnose. This session, A Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain will address practical ways primary care physicians can improve recognition and treatment of neuropathic pain.
Objectives
Recognize signs and symptoms of neuropathic pain to increase identification of patients with neuropathic pain
Evaluate available treatment options for neuropathic pain and their appropriateness for your patient population to improve outcomes in these patients
Faculty
Katherine E. Galluzzi, DO, FACOFP
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
David Bazzo, MD
Overview
This program is designed to provide primary care providers with information about the state of the science and evidence-based strategies for the accurate identification and comprehensive treatment of osteoporosis.
Objectives
Identify appropriate diagnostic tools & procedures that can be employed for early diagnosis of osteoporosis
Evaluate the treatment strategies, including methods of administration and MOAs of various antiresorptive agents that are currently available to prevent fractures and treat osteoporosis
Faculty
Abby Abelson, MD
Richard Pittsley, MD
Overview
Atherothrombotic disease, including acute coronary syndrome, stroke/TIA and PAD (peripheral arterial disease), continues to be a world-wide challenge in terms of morbidity, premature death, and disability with tremendous costs to patients, health care systems and society. The diffuse nature of atherothrombosis (cardiovascular, cerebrovascular, or peripheral arterial) and the heightened risk of recurrence represent major challenges to the clinician. This lecture will overview current studies and treatment guidelines for PAD, ACS and Stroke and explore the role of primary care in long-term treatment of these patients.
Objectives
Faculty
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Ketan Sheth, MD
Medical Director, Lafayette Allergy and Asthma Clinic
Lafayette, IN
Myron Zitt, MD